| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 12/04/2022 | 22:05 | Business Wire | AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 08/04/2022 | 19:05 | Business Wire | AbCellera Presents Data on T Cell Engager Platform at AACR 2022 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 04/03/2022 | 22:52 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 25/02/2022 | 21:55 | Edgar (US Regulatory) | Post-effective Amendment to Registration Statement (pos Am) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 25/02/2022 | 21:51 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 25/02/2022 | 20:16 | Edgar (US Regulatory) | Annual Report (10-k) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 24/02/2022 | 22:05 | Business Wire | AbCellera Reports Full Year 2021 Business Results | NASDAQ:ABCL | AbCellera Biologics Inc |
| 23/02/2022 | 22:05 | Business Wire | AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools | NASDAQ:ABCL | AbCellera Biologics Inc |
| 16/02/2022 | 12:00 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 15/02/2022 | 23:19 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 15/02/2022 | 00:34 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 12/02/2022 | 00:58 | Business Wire | AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 11/02/2022 | 22:59 | Dow Jones News | Lilly Antibody Bebtelovimab Gets FDA EUA for Certain Mild-to-Moderate Covid-19 Patients | NASDAQ:ABCL | AbCellera Biologics Inc |
| 11/02/2022 | 22:05 | Business Wire | AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 11/02/2022 | 20:49 | Edgar (US Regulatory) | Schedule 13g | NASDAQ:ABCL | AbCellera Biologics Inc |
| 11/02/2022 | 01:40 | Business Wire | Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments | NASDAQ:ABCL | AbCellera Biologics Inc |
| 04/02/2022 | 00:55 | Edgar (US Regulatory) | Annual Statement of Changes in Beneficial Ownership (5) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 27/01/2022 | 22:05 | Business Wire | AbCellera to Report Full Year 2021 Financial Results on February 24, 2022 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 21/12/2021 | 13:47 | TipRanks | Bloom Burton Initiates a Buy Rating on AbCellera Biologics (ABCL) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 07/12/2021 | 15:00 | Business Wire | AbCellera Announces Changes to Its Board of Directors | NASDAQ:ABCL | AbCellera Biologics Inc |
| 03/12/2021 | 23:48 | Edgar (US Regulatory) | Amended Statement of Changes in Beneficial Ownership (4/a) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 03/12/2021 | 22:05 | Business Wire | AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 02/12/2021 | 15:00 | Business Wire | AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer | NASDAQ:ABCL | AbCellera Biologics Inc |
| 10/11/2021 | 22:18 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 09/11/2021 | 22:05 | Business Wire | AbCellera Reports Q3 2021 Business Results | NASDAQ:ABCL | AbCellera Biologics Inc |
| 04/11/2021 | 21:05 | Business Wire | AbCellera Announces Virtual Presentations at Investor Conferences in November | NASDAQ:ABCL | AbCellera Biologics Inc |
| 02/11/2021 | 21:04 | Business Wire | Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 14/10/2021 | 22:05 | Business Wire | AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 23/09/2021 | 00:00 | Business Wire | AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies | NASDAQ:ABCL | AbCellera Biologics Inc |
| 21/09/2021 | 19:55 | Business Wire | Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19 | NASDAQ:ABCL | AbCellera Biologics Inc |